Atossa Therapeutics, Inc.

ATOS • Biotechnology

$2.52

▼ -0.01 (-0.40%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$22.45M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 5.53Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 13, 2026, 1:04 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.52

Change-0.40%

Shares Out8.91M

Market Cap$22.45M

Enterprise Value$-3.64M

52W Range1.70 - 19.35

Beta1.25

P/E-0.60

P/B0.84

P/FCF-0.63

EV/EBITDA0.12

EV/FCF0.10

Price$2.52

Change-0.40%

Shares Out8.91M

Market Cap$22.45M

Enterprise Value$-3.64M

52W Range1.70 - 19.35

Beta1.25

P/E-0.60

P/B0.84

P/FCF-0.63

EV/EBITDA0.12

EV/FCF0.10

Earnings Yield-167.97%

FCF Yield-159.39%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio5.53

Quick Ratio5.53

Target$42.50

Target Upside1586.51%

Target Median$42.50

Target Range10.00 - 75.00

Volume31.17K

Avg Volume123.67K

EPS Surprise0.11

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

87/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 5.53Weak profitability

Analyst view

Analyst sentiment and price target

ATOS

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

90/100

Bullish

Hold

Bearish

Price Target

2026-08-13

Low

$10.00

Mean

$42.50

Median

$42.50

High

$75.00

Company Overview

IPO: 11/8/2012

Industry: Biotechnology

P/B i: 0.84

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.00

Current Ratio: 5.53

Quick Ratio: 5.53

Status: Good

Insider Transactions

Recent executive and insider activity

Cigler Tessa

Transaction: 05/12/2026

BUY

Change

+10,000

Price

Not reported

Filing

05/14/2026

Type

BUY

Galli Stephen J

Transaction: 05/12/2026

BUY

Change

+10,000

Price

Not reported

Filing

05/14/2026

Type

BUY

Finn Jonathan

Transaction: 05/12/2026

BUY

Change

+10,000

Price

Not reported

Filing

05/14/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Cigler Tessa	BUY	+10,000	Not reported	05/12/2026	05/14/2026
Galli Stephen J	BUY	+10,000	Not reported	05/12/2026	05/14/2026
Finn Jonathan	BUY	+10,000	Not reported	05/12/2026	05/14/2026
Remmel H. Lawrence	BUY	+10,000	Not reported	05/12/2026	05/14/2026
Chen Shu-Chih	BUY	+10,000	Not reported	05/12/2026	05/14/2026
Steinhart Richard I	BUY	+10,000	Not reported	05/12/2026	05/14/2026
QUAY STEVEN C	BUY	+65,000	Not reported	03/27/2026	03/31/2026
Daniel Mark James	BUY	+63,000	Not reported	03/26/2026	03/30/2026
QUAY STEVEN C	BUY	+331,674	Not reported	01/20/2026	01/30/2026
QUAY STEVEN C	BUY	+325,203	Not reported	01/20/2026	01/22/2026
QUAY STEVEN C	BUY	+950,000	$0.60	01/20/2026	01/22/2026
Daniel Mark James	OTHER	0	Not reported	10/14/2025	10/21/2025
Daniel Mark James	BUY	+578,000	$1.03	10/14/2025	10/21/2025
QUAY STEVEN C	BUY	+11,239	$0.88	05/21/2025	05/22/2025
Cigler Tessa	BUY	+125,000	$0.99	05/15/2025	05/16/2025
Steinhart Richard I	BUY	+125,000	$0.99	05/15/2025	05/16/2025
Remmel H. Lawrence	BUY	+125,000	$0.99	05/15/2025	05/16/2025
Galli Stephen J	BUY	+125,000	$0.99	05/15/2025	05/16/2025
Rees Heather	BUY	+543,785	$0.99	05/15/2025	05/16/2025
QUAY STEVEN C	BUY	+1,366,062	$0.99	05/15/2025	05/16/2025

About the Company

Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.

Source - link

Peers

CGTX CLNN COYA GLSI IMMX ONCY SRZN TIL TVGN WHWK

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026. "During the quarter, we executed well across the business," stated Dr. Steven Quay, M.D.

PRNewsWire

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant models Findings suggest potential for combination with abemaciclib SEATTLE, July 28, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced the publication of a peer-reviewed preclinical study in npj Breast Cancer evaluating five novel chemical entities structurally related to (Z)-endoxifen. The study titled, "Novel (Z)-endoxifen-related new chemical entities exhibit potent anti-cancer activity in ERα+ breast cancer," reported anti-estrogenic and anti-cancer activity across multiple estrogen receptor-positive breast cancer models, including models harboring clinically relevant activating mutations in ESR1.

PRNewsWire

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers

Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndrome SEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet clinical need, today announced that a poster presentation titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome" was presented at the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers, which took place July 18-20, 2026, in Vancouver, BC, Canada. Presentation Details Session Type: Poster Session A Date: Saturday, July 18, 2026, 7:30-9:30 pm PT Abstract Number: A010 Location: AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers, Vancouver, BC, Canada Poster Title: Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome Presenter: Sandra Hammer, PhD, Atossa Therapeutics Inc. Summary: The poster supports a dual mechanism of action for (Z)-endoxifen in estrogen-driven pathology relevant to McCune Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP): the blockade of ER-mediated transcription downstream of autonomous estrogen production and suppression of PKC-β/AKT-associated proliferative and cell-cycle signaling.

PRNewsWire

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the "Series Warrants") and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance.

PRNewsWire

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 1,363,638 shares (the "Shares") of its common stock, par value $0.18 per share ("Common Stock") (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,638 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,638 shares of Common Stock (such warrants, collectively, the "Series Warrants") and accompanying Series Warrants in a registered direct offering. The Series Warrants will be exercisable six months following the date of issuance.

PRNewsWire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-08	-1.22	-1.11	0.11
2026-03-25	-1.1375	-1.19	-0.0525
2025-11-12	-1.05	-1.05	0
2025-08-12	-0.06	-0.07	-0.01
2025-05-13	-0.06	-0.05	0.01
2025-03-25	-0.06	-0.05	0.01
2024-11-12	-0.06	-0.05	0.01
2024-08-12	-0.05	-0.05	0
2024-05-13	-0.07	-0.05	0.02
2024-04-01	-0.05	-0.06	-0.01
2023-11-13	-0.07	-0.05	0.02
2023-08-14	-0.06	-0.06	0